Prolotherapy Injections Brisbane

The short answer

Prolotherapy is a dextrose injection treatment for selected persistent musculoskeletal pain. It is most often considered when a diagnosis is reasonably clear, sensible first-line care has not produced enough progress, and the potential benefit is worth the cost, discomfort and uncertainty.

It is not one treatment for every painful joint. The strongest clinical research is concentrated in a few areas—particularly knee osteoarthritis, lateral elbow tendinopathy and plantar heel pain—while evidence for many other uses advertised online is sparse or inconsistent.

At Back Pain Doctor in Milton, Brisbane, prolotherapy is used as one part of a management plan. That plan may also include education, progressive exercise, load modification, weight management, medication review, physiotherapy, shockwave therapy or a different injection. The injection is not allowed to displace treatment with stronger evidence.

What prolotherapy actually is

The word prolotherapy describes an injection technique rather than a single standardised product. Most contemporary musculoskeletal prolotherapy uses sterile hypertonic dextrose—glucose at a concentration higher than that found naturally in blood—sometimes mixed with local anaesthetic.

Depending on the diagnosis, small volumes may be injected:

• into a joint;
• around a tendon or ligament attachment;
• into a painful enthesis, where tendon or ligament meets bone;
• around a joint capsule; or
• at several related targets during the same session.

The concentration, total volume, number of sites and number of sessions vary across both clinical practice and research trials. That variation matters: the label “prolotherapy” does not guarantee that two clinics are delivering the same protocol.

Prolotherapy is not PRP or stem-cell treatment

Prolotherapy usually uses dextrose from a sterile pharmaceutical preparation. Platelet-rich plasma is made by processing a sample of your own blood. Stem-cell procedures use an entirely different category of biological material.

These treatments are sometimes grouped together under “regenerative medicine”, but that umbrella term can create more certainty than the evidence supports. A reduction in pain is not proof that a structure has regenerated. We use the specific treatment name and discuss the evidence for the specific diagnosis.

How might dextrose prolotherapy work?

Several mechanisms have been proposed. Hypertonic dextrose can alter the local cellular environment and may trigger a short-lived inflammatory and healing response. Laboratory research describes effects on cell signalling, growth-factor activity and connective-tissue cells. Lower concentrations of dextrose may also influence pain signalling around sensitive peripheral nerves.

Those mechanisms are biologically plausible, but they do not prove that the treatment works clinically. A laboratory finding, an ultrasound appearance and a meaningful improvement in a person’s pain are different outcomes. The best test remains a well-designed trial comparing prolotherapy with a credible placebo or an active treatment.

It is safest to describe the clinical aim in practical terms: reduce pain and improve function enough to support useful movement and rehabilitation. Claims that prolotherapy predictably tightens ligaments, permanently stabilises the spine or regrows cartilage go beyond what human research has established.

Who might reasonably consider prolotherapy?

The decision begins with diagnosis, not with a request for a particular injection. A reasonable candidate generally has:

1. a persistent problem with a clinically plausible pain source;
2. symptoms that affect work, sleep, sport or ordinary activity;
3. a genuine trial of appropriate first-line management;
4. no urgent surgical, neurological, inflammatory or systemic explanation being missed;
5. a target that can be reached safely; and
6. realistic expectations about benefit, uncertainty and time course.

Someone may be a poor candidate when the pain source is unclear, symptoms are widespread and non-specific, the main problem is severe mechanical deformity, or an injection is being used to avoid rehabilitation entirely.

Evidence for knee osteoarthritis

Knee osteoarthritis is the joint condition with the most prolotherapy research. Several randomised trials have compared intra-articular or combined intra- and extra-articular dextrose injections with saline, exercise, corticosteroid, hyaluronic acid or other injection treatments.

A 2020 blinded randomised trial involving 76 people reported better WOMAC pain and function outcomes at 52 weeks after four dextrose injection sessions than after saline injections. A 2024 systematic review and meta-analysis found favourable pooled results for some pain, stiffness and functional outcomes, but heterogeneity was substantial and not every pooled comparison was statistically significant.

An earlier systematic review of 11 studies concluded that prolotherapy may provide pain benefit and appeared reasonably safe in the available trials, while also highlighting that most studies had a high risk of bias. That combination—promising results but uneven certainty—is why different reviews can sound more positive or more cautious while examining overlapping evidence.

Australian guidance is important context. The RACGP knee and hip osteoarthritis guideline made a conditional recommendation against offering dextrose prolotherapy routinely, based on the limited evidence available during its review. That 2018 guideline predates several newer publications, but it remains an Australian guideline and should not be hidden from patients.

Our practical interpretation is:

• exercise, education and weight management where relevant remain foundational;
• prolotherapy does not reverse osteoarthritis or regrow a normal joint surface;
• the evidence is more credible for the knee than for the hip or shoulder;
• it may be discussed for persistent symptomatic knee osteoarthritis after first-line care;
• severe end-stage arthritis is less likely to be rescued by an injection; and
• progress should be measured with function and symptom goals, not assumed from completing a prepaid series.

You can read the broader management approach on our knee osteoarthritis guide.

Evidence for tennis elbow

Lateral elbow tendinopathy—often called tennis elbow—is among the better-studied tendon indications. A 2022 systematic review and meta-analysis pooled eight randomised trials involving 354 participants. It found clinically relevant short-term improvements in pain and arm function compared with active non-surgical controls, while noting that larger high-quality comparisons are still required.

A 2024 review of randomised prolotherapy trials in sports-related tendinopathy also found the most consistent research in lateral elbow, rotator cuff and plantar fascia conditions. Reviews are not unanimous, however. An earlier meta-analysis across tendon, fascia and ligament injuries judged the overall evidence insufficient once studies were pooled across different body regions and comparators.

That disagreement is a reminder not to generalise “prolotherapy works for tendons”. Results in a lateral elbow trial do not automatically apply to the Achilles tendon, hamstring origin or rotator cuff. For persistent tennis elbow, prolotherapy can be one option after a loading programme and diagnosis review, alongside focused shockwave therapy, PRP and continued rehabilitation.

Evidence for plantar heel pain

Persistent plantar heel pain has several possible contributors. The plantar fascia may be involved, but calf capacity, footwear, load change, nerve symptoms and other diagnoses also matter.

A 2023 meta-analysis of eight randomised trials found short-term improvements in pain and foot function with dextrose prolotherapy. It did not establish clear long-term superiority over active alternatives such as shockwave, corticosteroid or PRP, and the authors called for better evidence on concentration, volume, injection site and number of treatments.

This makes prolotherapy a possible option for selected persistent cases, not the automatic first step. A progressive calf and foot loading plan, footwear changes where relevant and a review of the diagnosis remain central. Shockwave therapy has a separate evidence base and may be discussed as a non-injection alternative.

Rotator cuff, Achilles and other tendinopathies

Clinical trials exist in several tendon conditions, but the volume and quality of evidence vary sharply.

• Rotator cuff tendinopathy: small trials and systematic reviews suggest possible benefit in selected persistent presentations. Results should not be extrapolated to a full-thickness tear, frozen shoulder or glenohumeral osteoarthritis.
• Achilles tendinopathy: the evidence is thinner. One trial included in recent reviews suggested that combining prolotherapy with eccentric loading improved symptoms faster than either approach alone, but one small study cannot define routine care.
• Patellar, gluteal and hamstring tendinopathy: evidence is limited or absent for many specific presentations. A plausible target is not the same as a proven indication.
• Acute tendon or muscle tears: prolotherapy is not a substitute for diagnosis, protection, rehabilitation or surgical review where indicated.

The correct question is not “does prolotherapy work for tendons?” It is “what evidence exists for this tendon, at this stage, compared with the alternatives available to me?”

Sacroiliac joint and low-back pain

Back pain is not one disease. It may arise from joints, discs, nerves, muscles or referred sources, and sometimes no single structure explains it. That makes broad claims about spinal prolotherapy especially problematic.

The US Department of Veterans Affairs systematic review found that evidence for chronic non-specific low-back and sacroiliac pain was very uncertain. Trials used different targets, concentrations, co-interventions and definitions of pain. A small randomised trial of selected sacroiliac joint pain reported longer-lasting improvement after intra-articular dextrose than after corticosteroid, but it needs replication — the full evidence for this joint, including a real-world cohort in which only 23 per cent of 103 patients reached a clinically important improvement, is set out on the sacroiliac joint prolotherapy page.

Prolotherapy is therefore not presented here as a general treatment for “weak ligaments”, disc degeneration, sciatica or ordinary lower-back pain. It may be discussed when the clinical picture supports a specific target—such as carefully selected sacroiliac joint pain—and when more established care has not been enough. Progressive neurological loss, bladder or bowel disturbance and other back-pain red flags require urgent assessment, not prolotherapy.

Hip and shoulder osteoarthritis

Evidence from knee osteoarthritis cannot simply be transferred to every joint. Hip and shoulder injections involve different anatomy, disease patterns and procedural considerations.

There are no comparable bodies of randomised evidence establishing dextrose prolotherapy for hip or glenohumeral osteoarthritis. The RACGP guideline specifically noted the lack of high-quality hip evidence. If hip or shoulder pain is being driven by an adjacent tendon—such as gluteal tendinopathy or rotator cuff disease—the treatment discussion should use evidence for that tendon problem rather than relabelling it as treatment of the arthritic joint.

For this reason, knee osteoarthritis is identified explicitly as the best-studied OA indication on this page. We do not imply that a result in the knee proves benefit in the hip or shoulder.

Why guidelines and recent reviews do not all agree

Patients often find a positive meta-analysis and a cautious guideline and wonder which one is correct. Both may be accurately reporting different evidence windows and using different decision thresholds.

Guidelines consider more than whether a pooled result reaches statistical significance. They also assess bias, consistency, clinical importance, safety, feasibility, cost and whether results apply outside specialist research settings. A newer trial can make an intervention look more promising without resolving all of those questions.

For prolotherapy, the main sources of uncertainty include:

• small trials;
• different dextrose concentrations and injection targets;
• variable use of ultrasound guidance;
• exercise or other treatment being added to one or both groups;
• different outcome measures and follow-up periods;
• difficulty creating a convincing injection placebo; and
• limited ability to detect uncommon complications.

The honest conclusion is not that prolotherapy is proven for everything or useless for everything. It is that evidence is encouraging in a small number of diagnoses and uncertain in many others.

Prolotherapy compared with other options

Prolotherapy versus corticosteroid

Corticosteroid aims to reduce inflammation and can provide relatively rapid relief in selected inflammatory or highly irritable presentations. Dextrose prolotherapy has a different rationale and generally a slower expected time course. Some tendon studies report better longer-term outcomes with prolotherapy, but results vary by diagnosis. Repeated corticosteroid near certain tendons may have disadvantages, while prolotherapy involves its own cost, soreness and uncertainty.

Prolotherapy versus PRP

PRP requires a blood draw and processing system, making it more expensive and less standardised. Prolotherapy uses a simpler pharmaceutical solution. Head-to-head knee and tendon studies do not establish one universal winner. The relevant comparison is condition-specific, and sometimes neither injection is the best next step.

Prolotherapy versus shockwave

Shockwave is non-invasive and has a substantial evidence base for some chronic tendinopathies. Prolotherapy involves needles and injectate. In plantar heel pain and elbow pain, trials compare them with mixed results across time points. Patient preference, target depth, previous treatment and the strength of evidence for the diagnosis all matter.

Prolotherapy versus rehabilitation

This is usually the wrong comparison. An injection should support a plan to regain capacity, not replace it. Many prolotherapy studies include exercise or loading in both groups, and the combined approach may be more sensible than treating the injection as a standalone fix.

Assessment before a prolotherapy injection

The consultation is designed to answer three questions:

1. What is the most likely diagnosis? The name on an old scan is not always the current pain source.
2. Is an injection likely to change the plan? If appropriate loading has not yet been tried, that may be the higher-value next step.
3. Can the target be treated safely? Anatomy, medication, infection risk, bleeding risk and other health conditions matter.

Assessment may include movement testing, neurological examination, review of previous imaging and point-of-care ultrasound where relevant. New imaging is ordered only when it is likely to clarify the diagnosis or alter management.

The discussion also establishes measurable goals. “Less pain” is important but broad. Walking distance, stairs, sleep, work tolerance, grip strength or return to a particular activity provide more useful review points.

Why ultrasound guidance may matter

Some superficial targets can be located clinically. For deeper joints, small tendon attachments and areas near nerves or vessels, ultrasound can improve visualisation of the needle path and the structure being treated.

Where a target cannot be seen adequately with ultrasound, or the needle path is too deep or too close to structures that must be avoided, the injection is not approximated here. It is referred to a radiologist to perform under CT guidance, which shows those targets directly.

Ultrasound guidance does not turn an ineffective treatment into an effective one. It addresses placement and procedural safety, not the biological uncertainty of the injectate. We use it where accurate targeting adds value and explain when a procedure is based on surface anatomy instead.

What happens during treatment?

A typical appointment involves:

1. confirming that symptoms and health circumstances have not materially changed;
2. reviewing the planned target and obtaining consent;
3. positioning you so the area can be reached safely;
4. cleaning the skin and preparing a sterile field;
5. using ultrasound when appropriate;
6. placing the dextrose solution into or around the selected structure; and
7. providing written or verbal aftercare and a rehabilitation plan.

The number of needle entries and total volume depend on the diagnosis. A single intra-articular knee injection is different from treating several attachment points around an elbow or pelvic structure.

What does recovery feel like?

Temporary aching, stiffness, bruising or a flare in familiar pain can occur after the local anaesthetic wears off. This commonly settles over several days. A flare is not proof that a healing response has occurred, and absence of soreness does not mean the treatment failed.

Most people can walk out of the clinic and continue light daily activity. Heavy loading, impact exercise or repetitive work may be reduced briefly, then reintroduced according to the treated structure and symptom response.

You should contact the clinic promptly if pain is escalating rather than settling, or if there is increasing redness, warmth, swelling, fever, new neurological change or another unexpected symptom.

When should improvement occur?

Prolotherapy is not intended as an immediate anaesthetic fix. Local anaesthetic can briefly reduce pain on the day, but that does not predict the longer-term result.

If treatment helps, change is usually judged over several weeks. A planned course may involve sessions approximately two to six weeks apart, but there is no evidence-based number that suits every diagnosis. We set review points and look for progress in both symptoms and function.

An open-ended series is not appropriate. If the diagnosis remains uncertain, adverse effects outweigh benefit, or objective progress is absent, the plan should be reconsidered rather than automatically repeating the same procedure.

Risks and limitations

Common short-term effects include:

• injection discomfort;
• local soreness or stiffness;
• bruising or minor bleeding;
• a temporary flare in pain; and
• brief numbness or weakness from local anaesthetic near the treated area.

Uncommon but important risks include infection, allergic reaction, injury to a nerve or vessel, unintended injection into another structure and a prolonged pain flare. Risk varies with the body region and technique. Small trials cannot reliably exclude rare complications simply because none were reported.

The non-procedural risks matter too: cost, time, delayed access to a more appropriate treatment and the possibility that symptoms do not improve.

Who may need to avoid or postpone prolotherapy?

Treatment may be postponed or avoided with active infection, significant illness, poorly controlled medical conditions, an unsafe bleeding risk, allergy to a required component or when the target cannot be approached safely. Pregnancy and other individual circumstances require a specific discussion.

Tell us about anticoagulants, antiplatelet medicines, diabetes medicines, immune-suppressing treatment, allergies and previous injection reactions. Do not stop prescribed medication on your own. If a medication change is relevant, it should be agreed with the clinician who manages it.

Questions worth asking any prolotherapy clinic

• What diagnosis are you treating?
• Which structure will be injected and why?
• Is the injection inside a joint, around a tendon or at several attachments?
• What evidence exists for this specific condition?
• What are the alternatives, including doing no injection?
• Will ultrasound guidance be used, and what does it add here?
• How many sessions are proposed and when will the plan be stopped?
• How will progress be measured?
• What is the full out-of-pocket cost?
• What rehabilitation should continue alongside treatment?

Clear answers are more useful than broad promises about “regeneration”.

Prolotherapy in Brisbane: our approach

Dr Joshua Hatch provides musculoskeletal assessment and selected ultrasound-guided injection treatment at Back Pain Doctor in Milton. The purpose of the initial consultation is not to sell a procedure. It is to establish the diagnosis, review what has already been tried and decide whether prolotherapy has a reasonable evidence-to-risk trade-off for your problem.

If another approach is more appropriate, that is the recommendation. If prolotherapy is reasonable, you will be told what evidence supports it, what remains uncertain, what the course may cost and what would make us stop or change direction.

You can book a musculoskeletal assessment or review the broader list of non-surgical treatments before deciding.

Evidence summary

The current evidence supports a measured position:

• knee osteoarthritis has the largest joint evidence base, but guidelines remain cautious;
• lateral elbow tendinopathy and plantar heel pain have supportive randomised trials;
• evidence for other tendons varies and should not be generalised;
• non-specific back pain, hip OA and shoulder OA do not have comparable support;
• serious complications appear uncommon in published studies, but rare harms are difficult to quantify; and
• prolotherapy should sit alongside rehabilitation and diagnosis-specific care, not replace them.

That is enough evidence to justify a careful discussion in selected cases. It is not enough to justify a guarantee.